Major Healthcare Shifts: J&J's Groundbreaking Psoriasis Pill, FDA Leadership Change, and Legal Blocks to HHS Vaccine Policy
Today marks a confluence of significant regulatory and market developments that reshape the healthcare landscape.
These developments, combined with new evidence of 150,000 uncounted early COVID-19 deaths, underscore the critical intersection of regulatory oversight, market…
Johnson & Johnson's breakthrough with the first oral psoriasis treatment comparable to injectables signals a potential disruption in the multibillion-dollar autoimmune market. Meanwhile, the FDA faces a leadership vacuum in infectious diseases with Adam Sherwat's departure, just as a federal court blocks HHS Secretary Kennedy's attempts to reduce childhood immunization recommendations - highlighting the ongoing tension between political appointees and established medical con…
One pattern. Trace it.
- 01
A pattern worth naming
Watch for: 1) Market response to J&J's oral psoriasis treatment pricing in next 30 days; 2) FDA's appointment of new infectious disease leadership within 60 days; 3) Potential appeals or modifications to the federal court's vaccine policy ruling; 4) Implementation of new disease surveillance methods based on COVID-19 death count revelations; 5) Additional pharmaceutical companies pursuing oral alternatives to injectable treatments in next quarter.
Ask your CFO whether the unit economics on every new service line still pencil under the new rate environment.
By Joseph Lancaster, Editor — with research from Pine Needle's intelligence layer.
The next argument lands tomorrow at 6 a.m. Pacific. Get it in your inbox →